why choose us

First received: November 16, 2023

Clinical Trial: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Study Status: Completed

Recruit Status: RECRUITING

Condition: B-Cell Lymphoblastic Leukemia

Study Type: INTERVENTIONAL


Official Title: Phase 2 Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Brief Summary: This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy

Read more